This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body. This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.
Age range
30 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Amount of AZD4144 excreted (Ae)
Timeframe: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)
Timeframe: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted (CumAe)
Timeframe: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)
Timeframe: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the dose
Timeframe: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
80% or more of the radioactivity recovered in excreta
Timeframe: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose